made in each subject according to a prearranged statistical design. The reactivity of the K12, K121 dilution, and K13 suspensions among patients with active and inactive sarcoidosis was closely similar to that with the 'standard' S10 suspension and in accordance with the expected proportions of reactions in patients at different stages of sarcoidosis. The K12, K13, and 'standard' S10 suspensions yielded a negligible proportion of positive reactions among patients with active and quiescent pulmonary tuberculosis and among healthy subjects: thus, as judged by these tests each suspension showed a high degree of selectivity for sarcoidosis.
The results of this validation study are discussed in relation to the results of other studies in which lots 5 and 14 of K12 and early and late batches of a suspension prepared from another sarcoid spleen at the Commonwealth Serum Laboratories designated CSL and provided by Dr T. H. Hurley in Melbourne were employed. Using lot 5 of K12 positive reactions were found in an appreciable proportion of patients with Crohn's disease, ulcerative colitis, and tuberculous lymphadenitis. A closely similar rate of positive reactions was encountered among patients with Crohn's disease following tests with batch 0025 of CSL suspension and with another lot (lot 14) derived from spleen K12. A close concordance of results was obtained with lot 5 (K12) and with batch 0042 CSL among patients with ulcerative colitis, but at a lower rate of reactivity.
We conclude that positive reactions also occur in some diseases other than sarcoidosis and consider that the difficulties in determining the criteria for an acceptable test suspension become increasingly apparent as additional Kveim tests are made with one particular lot and with seqential lots of material from a 'validated' tissue source.
The human sarcoid spleen represents the best source supply of sequential lots of potentially acceptable of Kveim test material. Although satisfactory test test materials for general use over a prolonged period. suspensions can also be prepared from other tissues Unfortunately, the histological appearances of a affected by sarcoidosis, a spleen, once it has been sarcoid spleen give no guidance to either the reactivity validated, will by virtue of its size ensure an ample or the selectivity of suspensions prepared from it; in man. Kveim tests in patients with definite clinical sarcoidosis will determine the reactivity of the suspension: comparison with identical tests among patients with other granulomatous and nongranulomatous diseases (particularly tuberculosis) and among healthy subjects will determine its selectivity for sarcoidosis.
Objectives
The objectives of the present study were to assess the macroscopic and microscopic response at the Kveim test site four to six weeks after the intracutaneous injection of Kveim Table IV shows that there is a close correlation between the papule size and the microscopic reading (p < 0 001). The mean papule diameters were 3-8, 2 4, and 1P1 mm for those positive, equivocal, and negative on biopsy, respectively.
It is of interest that the mean papule sizes for the microscopically negative biopsies (as for all biopsies) were greater in patients with active sarcoidosis than in those with inactive sarcoidosis or pulmonary tuberculosis, and that these were in turn greater than in healthy subjects ( (table VI) , six were positive to 3 TU, five were positive to 100 TU only, and seven were negative to 3 TU and 100 TU. Of the 18 patients whose sarcoidosis was inactive at the time of testing, four were positive to 3 TU, three were positive to 100 TU only, and 11 were negative to 3 and 100 TU. Tuberculin tests were not made in connection with this study in the patients with tuberculosis or in the healthy subjects. were 5 of 9 and 2 of 9. These findings are closely similar to those with the 'standard' S10 suspension in this study, namely 5 of 9 patients with active, and 2 of 9 patients with inactive sarcoidosis. Hirsch et al (1961) reported the results of a study in which a Kveim suspension, again a type I of Chase and Siltzbach similar to the 'standard' S1O suspension used in the present study, was likewise injected intracutaneously into persons with sarcoidosis and various other diseases. Again the test sites were removed by punch biopsy four to six weeks after injection, and sections of these biopsies were assessed by two observers who were unaware of the clinical diagnosis. A positive Kveim test was found in 75 % of 71 patients with subacute active sarcoidosis and in 64% of 45 patients in whom active sarcoidosis was known to have been present for more than two years. The lower reactivity in subjects with inactive sarcoidosis appears to be related to the interval since onset of the disease (Siltzbach, 1961 a, b) .
With regard to the selectivity of the K12 suspension, one positive reaction was found among nine apparently healthy subjects and none among 18 patients with pulmonary tuberculosis. With the halfdilution, the figures were 0 of 9 and 0 of 18. Similarly, Hirsch et al (1961) found positive Kveim reactions in less than 5 % of 43 subjects with arrested tuberculosis or connective tissue disease, and among young schizophrenic men who had negative tuberculin tests.
The findings for the K12 suspension are similar to the more recent findings of the international Kveim test study reported by Siltzbach (1967) in which, of those with biopsy confirmed sarcoidosis of less than two years' duration, 62 % gave a positive reaction following tests with his suspension. Among those with 'chronic' lesions, 38 % responded, demonstrating again the waning of Kveim reactivity with the passage of time; only two (1 -2 %) positive reactions were seen, both in patients with leprosy, of the 173 subjects tested in the control group.
The findings of a negative Kveim test among some patients with recent active sarcoidosis remains unexplained. None of the patients in the present study were receiving corticosteroids during the period of Kveim testing, which is known to depress the Kveim reaction (James and Thompson, 1955; Nelson, 1957; Siltzbach, 1961a, b) . 880 jug. Despite these wide differences, the levels of reactivity of K12 and S1O were closely similar and that for K13 was only slightly less. Hence the alcohol-precipitable dry weight of test material can serve only as a very approximate guide to the activity of a test suspension which can be assessed only following biological assay in patients with sarcoidosis. Similarly, it is not possible to assess reliably, before validation in man, which sarcoid spleen will yield a potent test suspension. Thus Siltzbach (1964) reported his evaluation of 38 different tissue suspensions, of which only 18 were satisfactory. The remaining 20 were either too weak or elicited nonspecific granulomata. Putkonen (1943; stressed that the most active Kveim test suspensions were frequently obtained from patients whose Kveim test showed only a weak positive reaction, and it is of interest that the Kveim test in the donor of spleen K12 was only weakly positive and that for K13 was negative.
The suspension prepared from spleen K13 appeared to be slightly less reactive than spleen K12 or S10 as a source of Kveim test material, but the differences are not significant. KI 3 is a relatively small spleen and is for this reason less suited to yield a continued supply of validated Kveim material.
This study has in general confirmed the reactivity and selectivity of all the Kveim test suspensions in patients with active sarcoidosis but has not indicated whether these suspensions differ in their reactivity. It has also confirmed the greater reactivity of the Kveim test suspensions in active than in inactive sarcoidosis.
The findings on papule size are of interest in two respects. First, papules were found in 41 of 72 Kveim tests in patients with pulmonary tuberculosis, although none of these tests was positive on biopsy. In comparison, only 1 of 36 Kveim tests in healthy subjects showed a papule at the test site. Secondly, among those with a negative microscopic reading, the mean papule size was greater in patients with active or inactive sarcoidosis than in patients with tuberculosis or healthy subjects. This suggests that the papule size provides information supplementary to the microscopic reading in the interpretation of the Kveim test result. Mitchell et al (1969 Mitchell et al ( , 1970 and Mikhail and Mitchell (1971) , using lot 5 of spleen K12, a suspension which in this validation study yielded the expected proportion of positive reactions in patients at different stages of sarcoidosis and a negligible proportion in those with active or quiescent pulmonary parenchymal tuberculosis or among healthy subjects, found positive reactions in an appreciable proportion of patients with certain other diseases, including Crohn's disease (Mitchell et al, 1969 (Mitchell et al, , 1970 , ulcerative colitis , and tuberculous lymphadenitis (Mikhail and Mitchell, 1971 ). Moreover, they encountered a closely similar rate of positive reactions among patients with Crohn's disease after tests with an early batch (0025) of CSL suspension and with another lot (lot 14) derived from spleen K12 (Mitchell et al, 1970) . A close concordance of results was also obtained with lot 5 (K12) and with batch 0042 (CSL) in tests among patients with ulcerative colitis ), but at a lower rate of reactivity than in patients with Crohn's disease. Hurley and Bartholomeusz (1968) (Hurley and Bartholomeusz, 1968) , and later batches 005-006, which had earlier been shown to give microscopically positive tests among patients with diseases other than sarcoidosis (Izumi et al, 1974) , yielded positive tests among patients with sarcoidosis, tuberculosis, Hodgkin's disease, nonHodgkin's lymphoma, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and Weber-Christian disease. It is highly relevant that the early batch 0017-0023 used in the original validation produced the lowest percentage of positive reactions among patients with diseases other than sarcoidosis and that these early batches showed only 12 (1-7%) microscopically positive responses among 722 patient with a wide variety of diseases other than sarcoidosis and Crohn's disease in the continued international Kveim test study (1966) (1967) (1968) (1969) (Hurley and Bartholomeusz, 1971) .
The fulfilment of the elaborate design of this present study, which required careful matching of subjects in different clinical categories, turned out to be extremely laborious and time-consuming. The advantages it brought were very slight-marginally more precise assessments of the relative reactivity of the Kveim test in active and inactive sarcoidosis and of its specificity. It contributed nothing to the assessment of any differences in reactivity between the four test suspensions on which the findings of this study are inconclusive. In retrospect it was a mistake to have adopted so demanding a design, and this should also have been clear in prospect.
Differences in reactivity between two test suspensions can be satisfactorily established only by testing substantial numbers of patients with sarcoidosis with the two suspensions in parallel. For this purpose active sarcoidosis cases are to be preferred to inactive cases because of their greater reactivity to Kveim test suspensions, as confirmed by the present study. This approach has been adopted in our subsequent investigations of these and other Kveim test suspensions. With regard to the selectivity of a suspension for sarcoidosis (Mitchell and Scadding, 1974) , the difficulties in determining the criteria for an acceptable test suspension become increasingly apparent as additional Kveim tests are made with one particular lot and with sequential lots of test material from a 'validated' tissue source. We conclude that the possibility that positive reactions can be produced selectively in some other diseases following tests with a suspension that gives the expected proportions of reactions in patients with different stages of sarcoidosis and a negligible proportion of these in those with active or quiescent pulmonary tuberculosis must be considered. 
